PhorMed's lead technology, RP-323, is a

gene repair therapy

What we do

Discovering new approaches to therapy in the field of genomic medicine.

About Us

We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted gene repair, immunotherapy, and stem cell activator for treating neurological diseases, cancers and blood disorders.

Read More

Investor

We are happy to announce that you can now be part of this exciting technology and help make a difference by investing in PhorMed through crowdfunding.

 

INVEST IN PHORMED NOW

Research

RP-323 treats diseases upstream where issues start. It has the ability to add a needed phosphate to a pathway turning the switch on or off inside the DNA (differentiation), clearing the pathway allowing transcription of DNA and expresses a protein producing a change such as cell division (proliferation) or cause cell death(apoptosis).

                       

Read More

Patient

After multiple clinical studies RP-323 has been found to be safe and the company is now prepared to enter into the next phase of clinical trials advancing its pipeline in collaboration with two clinical sites in Atlanta Georgia.

Read More

RECENT NEWS

PhorMed Inc is committed to good corporate citizenship. Our policy is to conduct our business affairs honestly and ethically.


09/20/2019

PhorMed welcomes Prof Harold H Lee to its Advisory Board

On September 17, 2019, inventor, Prof. Ricard L. Chang, successfully recruited Professor Harold H. Lee to PhorMed’s Scientific Advisory Board. Prof. Lee will advise on the company’s medical writing needs. He is credited for the publishing of 4 novels, 20 peer reviewed publications, and holds 4 patents, in the field of developmental biology. “Professor Lee has extensive knowledge in differentiation, the company’s primary mechanism of action and is a much welcomed addition to the company.” said Dr. Moretz, CEO.


08/10/2019

PHORMED ADDS 3 MEMBERS TO ITS ADVISORY BOARD

PhorMed is pleased to add three members to its advisory board and is honored to announce Professor Xi Zheng, Professor Renping Zhou, and Sean O’Connell, Ph.D. These advisory board members have a combined 98 years of experience in oncology, neurology, and hematology, with 190 peer reviewed publications between them. “They are well received and are a great asset to the company. Their extensive knowledge of our technology and close workings with the inventor will help guide the technology to its end goals”, said Mr. Ben Chang, Chairman.


08/01/2019

PHORMED ACQUIRES 5 PATENTS FROM PROFESSOR RICHARD L CHANG

On August 1, 2019, PhorMed entered into multiple contracts to acquire five of Professor Ricard L. Chang’s patent inventions. These contracts cover patent assignments for the use of his compound, RP-323, in the treatment of Acute Myeloid Leukemia, Hodgkin’s Lymphoma, Parkinson’s disease, Stroke, and a new patent for treating platelets, Immune Thrombocytopenia Purpura. The company’s goals for these technologies are to develop first line treatments and create a new class of drug for neurological diseases.